* Second quarter 2009 revenue increased 1% year-over-year to    $260.6 million.  Revenue increased 4% in constant currency.   * Second quarter 2009 GAAP earnings per share (EPS) 54 cents, up    29 cents or 116% from last year's second quarter.   * Second quarter free cash flow of $23.9 million.  Total debt    declined to $895.6 million.   * Fiscal 2009 revenue and EPS guidance confirmed. 

Commenting on the results, Robert S. Weiss, Cooper's president and chief executive officer said, "We are very pleased with our second quarter results as we generated strong earnings growth, solid free cash flow and made progress with several key products including our silicone hydrogel spheres, Avaira(r) and Biofinity(r). Our Biofinity toric launch in the U.S. and Europe continues ahead of schedule, and our growth in the single-use modality remains strong. We remain committed to growing the business for the long term while prudently managing costs in today's economic environment."

Second Quarter Operating Highlights

    * Revenue $260.6 million, 1% above second quarter 2008, 4% in    constant currency.   * Gross margin 57% compared with 58% in last year's second quarter.   * Operating margin 16% compared with 11% in last year's second    quarter.   * Depreciation and amortization expense $21.0 million, including    $1.0 million in accelerated depreciation.   * Research and development $10.1 million, including a one-time    in-process R&D charge of $3.0 million, or 7 cents per share, for the     acquisition of certain distribution rights.   * Interest expense $10.8 million, or 4% of sales vs. $12.1 million,    or 5% of sales in last year's second quarter.   * Capital expenditures $20.0 million. 

Second Quarter CooperVision (CVI) Operating Highlights

    * Revenue $217.8 million, consistent with last year's second    quarter, up 4% in constant currency.   * Revenue by segment:                                                               Constant                                   (In      % of CVI           Currency                                thousands)   Revenue   %chg     %chg                                   2Q09       2Q09      y/y      y/y                                 --------   --------   ------   ------    Toric                        $ 65,393       30%     -11%      -1%    Multifocal                     14,601        7%       6%      17%    Single-use sphere              43,944       20%      11%      16%    Non single-use sphere, other   93,880       43%      -9%       1%                                 --------   --------    Total                        $217,818      100%     n/c        4%                                 ========   ========   * Revenue by geography:                                                               Constant                                   (In      % of CVI           Currency                                thousands)   Revenue   %chg     %chg                                   2Q09       2Q09      y/y      y/y                                 --------   --------   ------   ------    Americas                     $ 97,791       45%       3%       4%    Europe                         81,480       37%      -4%       4%    Asia Pacific                   38,547       18%       1%       5%                                 --------   --------    Total                        $217,818      100%     n/c        4%                                 ========   ========   * Revenue by material:                                                               Constant                                   (In      % of CVI           Currency                                thousands)   Revenue   %chg     %chg                                   2Q09       2Q09      y/y      y/y                                 --------   --------   ------   ------    Proclear                     $ 60,603       28%       1%      14%    Silicone hydrogel            $ 23,528       11%      88%     109%   * Gross margin 56% compared with 58% in the second quarter of 2008.   * Operating margin 16% compared with 12% in last year's second    quarter. 

Second Quarter CooperSurgical (CSI) Operating Highlights

    * Revenue $42.8 million, up 3% from last year's second quarter.   * Sales of products marketed directly to hospitals increased 18%    year-over-year to $14.0 million and now represent 33% of CSI's    total revenue up from 29% in last year's second quarter.   * Gross margin 61%, up from 59% in last year's second quarter.   * Operating margin 26%, up from 19% in last year's second quarter. 

2009 Guidance

The Company confirms fiscal 2009 guidance with revenue in the range of $1,030 million to $1,100 million, including CVI revenue of $865 million to $925 million and CSI revenue of $165 million to $175 million. GAAP EPS guidance for fiscal 2009 is confirmed in the range of $2.16 to $2.36.

Conference Call and Webcast

The Company will host a conference call today at 5:00 p.m. ET to discuss its second quarter 2009 financial results. The dial in number in the United States is +1-800-299-9630 and outside the United States is +1-617-786-2904. The passcode is 63788046. There will be a replay available approximately two hours after the call ends until Thursday, June 11, 2009. The replay number in the United States is +1-888-286-8010 and outside the United States is +1-617-801-6888. The replay passcode is 27011858.